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Abstract 
 
Background: Hepatorenal syndrome is a serious, potentially lethal complication of 
advanced cirrhosis. Different pharmacological therapies using vasoactive agents have 
been used to treat HSR. The most considered vasoconstrictor drug is Terlipressin. Many 
Systematic Reviews (SRs) and Meta-analyses (MAs) have been published addressing 
the efficacy of Terlipressin in comparison with other vasoactive agents. 
Objective: The aim of this study is to assess the overall reporting quality of Systematic 
Reviews and Meta-analyses on Terlipressin in Hepatorenal Syndrome.  
Methods: Five electronic databases were searched in August 2018 in order to locate all 
SRs and MAs that have been published from 2010 to 2018, reporting the efficacy of 
Terlipressin in HRS. The reporting quality of the included meta-analyses was evaluated 
based on the PRISMA statement.  Total PRISMA scores and frequencies of reporting 
each item were calculated and univariate linear regression analyses were performed to 
explore potential factors that influence the reporting quality of the articles.  
Results A total of 15 Meta-analyses were included. The results showed that the overall 
reporting quality was adequate, with mean PRISMA score = 21/27 (77 %).  Ten items 
were 100% reported while Objectives (20%) and Protocol and Registration (26, 7%) 
were the items that had the poorest adherence. The 26, 6% of the MAs were published 
in PRISMA – endorsing journals with a median JIF = 4. Most studies had as primary 
outcomes HRS reversal and mortality. Terlipressin was in all MAs statistically superior 
to placebo or no intervention in the reversal of HRS. However, terlipressin was also 
associated with more Adverse Events than placebo.  
Conclusions: The overall reporting quality of meta-analyses in Terlipressin in HRS was 
in general adequate. Objectives were the item having the poorest adherence. The main 
primary outcome of MAs was HRS reversal. Terlipressin was proved superior to 
Placebo considering HRS Reversal but was associated with more adverse events. To 
raise the reporting quality of meta-analyses on terlipressin in HRS, further, 
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Introduction  
 
Hepatorenal syndrome (HRS) is defined as the occurrence of renal failure in a patient 
with advanced liver disease in the absence of an identifiable cause of renal failure. (1) 
It is a severe, potentially fatal complication of decompensated liver cirrhosis and its 
optimum treatment is Liver Transplantation.  
The development of hepatorenal syndrome has been associated with the circulatory 
changes seen in cirrhosis of the liver subsequent to portal hypertension and 
vasodilation of the splanchnic arteries. (2) Portal hypertension and the vasodilation of 
the splanchnic arteries burden the cardiac effort and as a result, they reduce the 
cardiac output and systematic hypotension occurs. This systematic hypotension and 
peripheral vasoconstriction result in a reduction of the renal arterial perfusion. 
Consequently, renal homoeostatic mechanisms, such as the renin-angiotensin system, 
vasopressin, and the sympathetic nervous system, are overactive in order to maintain 
the renal arterial blood pressure.  
The International Club of Ascites has developed diagnostic criteria of Hepatorenal 
Syndrome, which are universally accepted and followed (Table 1). These criteria 
confirm that Hepatorenal syndrome is a diagnosis of exclusion. There are clinically 
two distinct types of Hepatorenal Syndrome. Type 1 HRS is characterized by a 
rapidly progressive renal failure defined by a doubling of the initial serum creatinine 
to a level greater than 2.5 mg/dl or 220 µmol/l in less than 2 weeks. (3) This 
impairment is usually precipitated by an aggravating event, such as acute bacterial 
infection and a dysregulated systemic inflammatory response. Type-1 HRS is 
associated with very poor prognosis and if it is left untreated, it has a 2-week 
mortality rate of  80%.  (1) Type-2 HRS is characterized by a moderate renal failure 
which follows a steady or slowly progressive course (serum creatinine greater than 
1.5 mg/dl or 133 µmol/l). Patients with type-2 HRS have a better prognosis with 
median survival around 6 months without transplantation. (1) 
 
Criteria for the diagnosis of Hepatorenal Syndrome – International Club of 
Ascites ( ICA)  
1. Presence of cirrhosis and ascites 
2. Serum creatinine >1.5 mg/dL (or 133 micromoles/L) 
3. No improvement of serum creatinine (decrease equal to or less than 1.5 
mg/dL) after at least 48 hours of diuretic withdrawal and volume expansion 
with albumin (recommended dose: 1 g/kg b.w. per day up to a maximum of 
100 grams of albumin/day) 
4. Absence of shock 
5. No current or recent treatment with nephrotoxic drugs 
6. Absence of parenchymal kidney disease as indicated by : 
 proteinuria >500 mg/day 
  microhematuria (>50 RBCs/high power field) and/or  
 abnormal renal ultrasound scanning) 
Table 1: Diagnostic Criteria of HRS - ICA 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:20 EEST - 137.108.70.13
4 
Larissa, September 2018 
Pharmacological therapies of Hepatorenal Syndrome aim to alter the circulatory 
derangements seen in cirrhosis by inducing splanchnic and systematic vasoconstriction 
in conjunction with volume expansion. For this reason, vasoactive agents are used 
together with albumin. The mainly used and studied vasoactive agents are Terlipressin, 
Noradrenaline, Midodrine with octreotide and Dopamine with furosemide. Among 
these agents, the most studied one is Terlipressin, because although it is the most used 
one with proven efficacy, it is not worldwide approved which study the efficacy and 
safety of the vasoactive agents in HRS have been published the last decade. Therefore 
many Systematic Reviews and Meta-analyses, as well, have tried to evaluate these trials 
and their conclusions in order to reach to a final inference and maybe suggest general 
guidelines for the treatment of Hepatorenal syndrome. 
Given the number of meta-analyses published the previous years and the fact that the 
aforementioned meta-analyses are often influential, the purpose of this study is to 
search the best currently available evidence systematically and evaluate the reporting 
quality of meta-analyses in Terlipressin in Hepatorenal Syndrome, published from 2010 





To be eligible for inclusion, studies had to fulfill the following criteria:   
1. Be described as “meta-analysis” or “systematic review” or both  
2. The RCT’s studied to be on adult patients with HRS   
3. Study therapeutic strategies including Terlipressin   
4. Be published in English as a full text  
5. Be published between 2010 and 2018 
 
Literature Search 
Using the aforementioned criteria, a comprehensive literature search was conducted 
during September 2018 using MEDLINE, PubMed, EMBASE (via Scopus), Web of 
Science, Cochrane Database of Systematic Reviews, NIM, AASLD, and EASL. 
Moreover, additional search in specific journals as Journal of Hepatology, Clinical 
Gastroenterology and Hepatology, Gut Journal and The Lancet Gastroenterology & 
Hepatology was conducted to identify relevant literature. Papers that were identified as 
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Data Extraction 
A sensitivity search strategy was performed using the medical subject heading terms 
(MeSH) and keywords: “hepatorenal syndrome,” “terlipressin,” “vasoactive,” 
“vasoconstrictor,” “systematic review,” and “meta-analysis”. Titles and abstracts were 
at first evaluated based on the inclusion criteria and full texts of potentially eligible 
studies were retrieved. Furthermore, data referring to the year and journal of 
publication, number of trials included in the meta-analysis and the number of authors 
involved in the study were extracted. 
 
Assessment of reporting quality and Data Analysis 
Assessment of reporting quality and Data Analysis 
The evaluation of the reporting quality of meta-analyses was performed based on 
PRISMA statement using as a tool the PRISMA checklist (Figure 1 & 2). This checklist 
is a questionnaire of 27 items divided into seven sections (Title, Abstract, Introduction, 
Methods, Results, Discussion, and Funding). The PRISMA authors have published a 
lengthy Explanation and Elaboration document, for a better understanding of the 
rationale and the content of each item. Meta-analyses were thoroughly reviewed in 
order to determine whether they fulfill each query or not. Some of the items on the 
checklist contain multiple components, so if most of them were met, the answer was 
“yes” and a score of 1 was assigned. Otherwise, the answer was considered as “no” and 
a score of 0 was assigned, as well. Thus, a total PRISMA score for each article was 
obtained with maximum probable total PRISMA score being equal to 27. This score 
was also expressed as frequency and proportion.  
Data were analyzed by the statistical software SPSS (IBM SPSS Statistics 25.0) and 
descriptive analysis was performed for characteristics. A P-value of 0.05 was set as a 
threshold of statistical significance.(5) Pearson correlation “r” was used to detect a 
potential correlation between reporting quality and specific variables (e.g. JIF). Finally, 






Through an electronic literature search, a total of 199 articles were initially identified. 
After omitting duplicates, 142 papers were screened and excluded on the basis of their 
Title and Abstract. The main reason for exclusion was the discrepancy with the 
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Figure 1: PRISMA checklist 
 
Figure 2: PRISMA checklist 
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eligibility criteria in respect of content (not about Terlipressin).  Then the remained full-
text articles were assessed for inclusion, from which 69 were rejected according to our 
criteria. Most of them were excluded due to deviation with the defined timeline of the 




Figure 3: Flow Chart of the study selection progress 
 
Review Characteristics  
Table 2&3 and Bar charts 1 & 2 display the general characteristics of the included meta-
analyses regarding year and journal of publication, number of authors, continent of 
origin, JIF, PRISMA endorsement, and funding. Table 3 summaries the descriptive 
analysis of Year of publication, Number of Authors and JIF. Most of the studies were 
published in 2017 (7/15, 46, 7%) (Chart 1). Journals of publication had a median JIF = 
4 and a range from 0, 90 to 53, 2. The meta-analysis by Facciorusso et. Al was published 
in Lancet Gastroenterology & Hepatology which has the greater JIF= 53, 2. Only 26, 
6% (4/15) of the journals of publication endorsed PRISMA statement. There was a 
mean = 4, 67 of authors per published meta-analysis, with 26, 7% having nAuthors = 
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4. (6).  No continent of origin distinguished from the others, as seen in Table 4 and Bar 




Author Year Continent n 
Authors 
Journal JIF PRISMA 
Endorsement 
Funding 
Mattos 2016 South 
America 
2 European Journal of 
Gastroenterology & 
Hepatology 
2,014 No - 
Nassar Junior 2014 South 
America & 
Europe 
5 PLOS ONE 2,766 Yes No 
Hiremath 2013 Asia 2 Indian Journal of 
Pharmacology 
0,902 No - 
Israelsen 2017 Europe & 
N. America 
7 The Cochrane 
Collaboration  
6,124 No No 
Sagi 2010 North 
America 
4 Journal of 
Gastroenterology & 
Hepatology 
3.483 No - 
Wang 2017 Asia 5 Medicine 2,028 No No 
Gluud 2012 Europe 4 The Cochrane 
Collaboration 
6,124 No No 
Dobre 2010 North 
America 
4 Int Urol Nephrol 1,564 No - 





53,254 Yes No 
Gifford  2017 Europe 3 Alimentary 
Pharmacology & 
Therapeutics 
7,357 Yes Yes 
Gluud 2010 Europe 4 Hepatology 14,079 No - 
Nanda 2017 North 
America 
5 Journal of Clinical 
Gastroenterology 
7,683 No - 
Zheng 2017 Asia 8 Expert Review of 
Gastroenterology & 
Hepatology 
2,963 No Yes 
Allegretti 2017 Europe & N. 
America 
8 The Cochrane 
Collaboration 
6,124 No No 
Sridharan 2017 Oceania 2 JGIM 4,005 Yes No 
 
Table  2: General Study Characteristics 
 
Institutional Repository - Library & Information Centre - University of Thessaly
07/06/2020 18:03:20 EEST - 137.108.70.13
9 
Larissa, September 2018 
 




Chart 1: %Proportion of Year of Publication 
 
 
Table 4: Frequency & proportion of Meta-analyses' Continent of Origin 
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Chart 2: %Proportion of Continents of Origin 
Table 5 depicts characteristics of meta-analyses regarding their content (e.g. number of 
trials, number of patients, intervention, and outcomes) and the quality of their included 
studies. Almost all of the meta-analyses studied exclusively RCT’s, with Hiremath’s 
meta-analysis being the exception (12) A median of n=10 RCT's was included in each 
meta-analysis, while 20% of them embody n=4 number of trials (Chart 3). The most 
common comparison was between Terlipressin and Placebo or Noradrenaline and the 
main primary outcomes were HRS Reversal and short-term Mortality. As for quality 
assessment, the Cochrane Risk of Bias Tool was used in 46, 6% (7/15) of meta-
analyses. The rest of the MAs used other quality assessment tools as GRADE and Jadad 
Score. Finally, the majority (46, 6%) of the meta-analyses conclude that have been 
based on low quality- high risk RCT's. Only two meta-analyses (Wang & Gluud 2010) 
have declared high trial quality. (10, 19) 
 
Chart 3: % Proportion of number of included trials 
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Table 5: Characteristics of Content & Quality of the included studies   *N/S = not stated    ¹ = only 




























Nassar Junior RCT’s 4 154 Terlipressin Vs 
Noradrenaline 









Hiremath Any 8 377 Terlipressin Vs 
Placebo  
Mortality - Nancy et 
al. 
N/S 




Mortality -  
HRS Resistance 
&  AE 
Quality of 







Sagi RCT’s 4 223 ¹ Terlipressin Vs 
Placebo 
HRS Reversal Recurrence 
HRS & 
Survival 
Jadad score Average 
Quality   








Jadad score High 
Quality 
Gluud RCT’s 6 N/S* Terlipressin Vs 
Placebo 
Mortality -  
HRS Resistance 










MBP – Cr 

















GRADE  Low – 
moderat
e Quality 
Gifford  RCT’s 12 700 ¹ Terlipressin Vs 
Placebo or 
Vasoactive 
HRS Reversal – 
















Nanda RCT’s 13 770 Terlipressin Vs 
Placebo or 
Vasoactive 
HRS Reversal Recurrence 
HRS & 
Survival 
Jadad score Average 
Quality   
Zheng RCT’s 11 685 ¹ Terlipressin Vs 
Placebo or 
Noradrenaline 







Allegretti RCT’s 9 534 Terlipressin Vs 
Placebo 
Mortality -  
HRS Resistance 






Sridharan RCT’s 16 762 Terlipressin Vs 
Placebo 
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Reporting Quality 
The mean PRISMA score of the 15 eligible MAs was mean= 21 (SD= 2, 1) out of 27 
and the mean adherence rate of all items to the checklist was 77, 7%. Therefore the 
overall quality of the meta-analyses can be described as moderate. None of the studies 
reported all of the items of PRISMA’s checklist. Two meta-analyses had the greater 
PRISMA Score with Score = 24/27. These were Israelsen et al. (2017) & Sridharan et 
al. (2017 (13, 18).  On the other hand, Sagi et al. (2010) meta-analysis succeeded the 
lowest PRISMA Score with a value of Score = 17/27 and then followed Zheng et al. 
(2017) meta-analysis with a PRISMA Score= 18/27 (17, 20). All the above are 
displayed in Table 6.  
Moreover, regarding the items of PRISMA checklist, ten of them were reported in every 
study. These items belonged one to the Introduction Section, four to the Methods, three 
to the Results and two to Discussion (Items 3, 7, 12, 13, 14, 17, 18, 20, 24, 25, Score 
100%). On the contrary, Objectives was the domain with the poorest adherence (Score= 
20%), following Protocol & Registration and Search with 26, 7% adherence with 
PRISMA. Although Objectives was included in every meta-analysis, very few of them 
were presented according to PRISMA explanation and elaboration. Table 7 & Chart 4 
display the reporting proportion of each domain. The items with the greatest adherence 
are highlighted and the others with the poorest are underlined  






Author PRISMA SCORE 
Frequency 
% 
Mattos 21/27 77 
Nassar Jr 19/27 70 
Hiremath 20/27 74 
  Israelsen 24/27 88 
    Sagi 17/27 62 
Wang 23/27 85 
Gluud 12’ 21/27 77 
Dobre 21/27 77 
Facciorusso 23/27 85 
Gifford  21/27 77 
Gluud 20/27 74 
Nanda 22/27 81 
  Zheng 18/27 66 
Allegretti 23/27 85 
  Sridharan 24/27 88 
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Section n Item  % Percentage 
of “Yes” 
TITLE 1 Title 80 
ABSTRACT 2 Structured Summary 46,7 
INTRODUCTION 3 Rationale 100 
 4 Objectives 20 
METHODS 5 Protocol & Registration 26,7 
 6 Eligibility Criteria 73,3 
 7 Information Sources 100 
 8 Search 26,7 
 9 Study Selection 80 
 10 Data collection 
progress 
73,3 
 11 Data Items 86,7 
 12 Risk of Bias in 
individual studies 
100 
 13 Summary Measures 100 
 14 Synthesis of Results 100 
 15 Risk Bias across 
studies 
79,9 
 16 Additional Analyses 86,7 
RESULTS 17 Study Selection 100 
 18 Study Characteristics 100 
 19 Risk of Bias Within 
studies 
80 
 20 Results of Individuals 
studies 
100 
 21 Synthesis of Results 93,9 
 22 Risk of Bias across 
studies 
33,3 
 23 Additional Analysis 86,7 
DISCUSSION 24 SummaryEvidence 100 
 25 Limitations 100 
 26 Conclusions 93,3 
FUNDING 27 Funding 60 
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Chart 4: Reporting Proportion of each PRISMA item 
 
 
Association of variables and study quality 
JIF, Year of publication, the number of Authors and the number of Studies included in 
meta-analysis were considered as potential factors affecting the reporting quality. This 
potential correlation was examined using the correlation coefficient “r.(21) As it 
emerges from the aforementioned analysis, there is a statistically significant moderate 
positive correlation between reporting quality of meta-analysis considering PRISMA 
Score and the Year of publication (r = 0,558) (Chart 5), meaning that the most recently 
published meta-analyses have greater reporting quality than the older ones. 
Additionally, there is also a statistically significant moderate positive correlation 
between PRISMA Score and the included number of studies (RCT’S) with r = 0,617.  
This indicates that meta-analyses with larger sample size have greater Quality. (Chart 
6).   
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Chart 6: Scatter plot of PRISMA Score in comparison with number of RCT'S 
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Finally, the analysis proved a negligible correlation between Reporting Quality of meta-
analysis and the Journal’s Impact Factor (r = 0,279) and number of Authors (r = 0,111). 
Below Scatter Plots between PRISMA Score and JIF, number of Authors are also 
presented. (Chart 7&8) (The interpretation of Pearson Correlation is based on MM 
Mukaka 2012 (22)).   
 
Chart 7: Scatter plot of PRISMA Score and JIF 
 
Chart 8: Scatter Plot of PRISMA Score - number of Authors 
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A potential association between reporting PRISMA Score and publication in PRISMA 
Endorsement Journal was examined as well. The existence of possible statistically 
significant difference in Quality Reporting was tested using T-test. From the analysis 
occurred that there is not a statistically significant difference in Quality Reporting 
regarding PRISMA Endorsement (Table 8). Likewise, the relation between Reporting 
Quality and meta-analyses supported by Cochrane Collaboration was tested and found 
no statistically significant difference. (Table 9) 
 
 




Table 9: T - test for PRISMA Score and Cochrane’s Meta-analyses 
 
A possible connection between Reporting Quality of a study and its studied Treatment 
comparisons was also examined, using One Way ANOVA and Post Hoc analysis. (4). 
Table 12 displays the results of the analysis. Five meta-analyses compared Terlipressin 
Vs Placebo, two Vs Noradrenaline, four Vs Placebo or Noradrenaline and four Vs 
Placebo or other vasoactive agents. Treatment Comparison was divided into four 
groups: 
 Group 1: Terlipressin Vs Placebo or Albumin or No intervention/Observation 
 Group 2: Terlipressin Vs Noradrenaline 
 Group 3: Terlipressin Vs Placebo or Noradrenaline  
 Group 4 : Terlipressin Vs Placebo or other Vasoactive agents 
 
There was not proved difference in Reporting Quality regarding Treatment 
Comparisons of meta-analysis.  
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Table 10: One Way ANOVA for PRISMA Score and Treatment Comparisons  
 
Table 11: Post Hoc Comparisons of Groups of Treatment Comparisons 
 
Table 12: Correlates of the reporting quality of meta-analysis regarding PRISMA Score and 
individual methodologic aspects 
1: according to “MM Mukaka 2012 “* t-test analysis **One-Way ANOVA analysis 
Variable Pearson’s R 
 
Correlation1 P – 
Value 
Significance 
JIF 0,279 Negligible 0,313 No 
Year 0,558 Moderate 
Positive 
0,031 Yes 
n Authors 0,111 Negligible 0,674 No 





- - 0,518 No 
Cochrane *  -  - 0,174 No 
Treatment 
Comparison** 
 -   -  0,504 No 
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Clinical Outcomes 
Nine of the meta-analyses reported in their analysis as outcome the resolution of HRS, 
comparing Terlipressin ± albumin with placebo ± albumin. Summarizing the outcomes 
of these meta-analyses it occurs that Terlipressin is almost 4-times superior to placebo 
or no treatment or albumin regarding the reversal of Hepatorenal Syndrome. Six out of 
nine studies report statistically significant difference and in the others p value is not 
stated. The Heterogeneity of the included studies of the meta-analyses range between 
0- 70 %. In Table 13 OR, 95% CI, Overall Effect Z & P – value of each study are 
presented. 










Sagi (2010) 3,66 2,15 6,23 0 4,78 ,00001 
Wang (2017) 4,69 2,23 11,00 57 3,93 ,00010 
Dobre (2010) 7,47 3,17 17,59 24 4,60 ,00001 
Gifford (2017) 2,54 1,51 4,26 52 3,52 ,00040 
Nanda (2017) 4,72 1,72 12,93 70 N/S ,00300 
Zheng (2017) ,24 ,07 ,65 N/S N/S  
Sridharan (2017) 6,70 2,10 21,30 N/S N/S  
Gluud (2010) 3,76 2,21 6,39 0 N/S*  
Facciorusso 
(2016) 
4,48 1,88 10,67 60 3,38 ,00070 
Table 13: Terlipressin Vs Placebo regarding HRS Reversal. Outcomes of each meta-analysis * N/S: 
Not Stated 
The Forest Plot (Chart 9) below depicts the OR (95%CI) of Terlipressin Vs Placebo 
considering the HRS Reversal of each study.  
 
 
Chart 9: Terlipressin Vs Placebo considering the HRS Reversal of each study 
Terlipressin Placebo 
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Eight of the meta-analyses compared Terlipressin Vs Noradrenaline for the resolution 
of HRS in their analysis. None of them proved superiority of the one treatment in 
comparison with the other in terms of HRS remission. The included studies of meta-
analyses had no Heterogeneity. All the above are displayed in table 14 and Chart 10. 
 










Nassar (2014) ,97 ,76 1,23 0 N/S* ,79 
Wang (2017) 1,01 ,65 1,57 0 ,05 ,96 
Dobre (2010) 1,23 ,43 3,54 0 ,30 ,70 
Gifford (2017) ,99 ,67 1,45 N/S* N/S* N/S* 
Nanda (2017) ,91 ,46 1,79 0 N/S* N/S* 
Zheng (2017) ,97 ,25 3,73 N/S* N/S* N/S* 
Mattos (2016) 1,03 ,81 1,31 0 ,25 ,80 
Facciorusso 
(2016) 
,89 ,47 1,69 0 ,36 ,72 
* N/S: Not Stated 




Chart 10: Terlipressin Vs Noradrenaline considering the HRS Reversal of each study 
Moreover, six meta-analyses studied the occurrence of serious Adverse Events and 
especially the occurrence of cardiovascular events presented with Terlipressin or 
Placebo. As it appears, Terlipressin is associated with higher risk of serious Adverse 
Events in relation with Placebo or Albumin or Observation. (Table 15 & Chart 11) 
Noradrenaline Terlipressin 
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Gluud (2012) 7,26 1,70 31,05 0 2,67 ,007 
Wang (2017) 1,57 ,63 3,93 4 2,75 ,006 
Gifford (2017) 3,56 1,64 7,72 0 3,21 ,001 
Gluud (2010) 9,00 2,14 37,85 0 N/S* N/S* 
 Sridharan (2017) 7,40 1,90 28,90 N/S* N/S* N/S* 
Allegretti (2017) 7,26 1,70 31,50 0 2,60 ,007 
* N/S: Not Stated 






Chart 11: Terlipressin Vs Placebo regarding Adverse Events 
 
Finally, two meta-analyses (Gifford, 2017 & Sridharan, 2017) (9, 18) studied the 
efficacy of bolus terlipressin administration Vs continuous infusion of Terlipressin, 
regarding the remission of HRS. According to these studies, continuous infusion is 
associated with higher reversal rates than bolus administration. Specifically RR= 1, 22 
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Discussion  
 
Hepatorenal syndrome is a serious complication of decompensated liver disease, with 
rapid progression. HRS can lead to multiple organ failure if left untreated. Although 
the best treatment of choice is liver transplantation, several pharmacological agents are 
being used in order to ameliorate renal function and reverse the syndrome. The most 
studied and widely used agent is Terlipressin. As there are no universal guidelines 
regarding treatment of Hepatorenal syndrome, many meta-analyses, and systematic 
reviews have been published the last decade in order to compare the efficacy and safety 
of Terlipressin in comparison with placebo or other vasoconstrictor drugs. Meta-
analyses and systematic reviews comprise important tools, which can provide high-
quality evidence and can lead to essential conclusions.  
In the present review, 15 meta-analyses being published from 2010 to 2018 were 
identified and were evaluated using the PRISMA Statement's checklist. The overall 
reporting quality of the existing meta-analyses is considered moderate with an average 
adherence rate of all items to the checklist being 77, 7%. Ten items of the checklist, 
which belonged mainly in sections of Methods & Results, were reported in all meta-
analyses. Most of the meta-analyses reported inadequately their Objectives, resulting 
in low rates of PRISMA compliance.  
PRISMA Score was considered as the value which represents the Quality of each study. 
Correlation analysis was performed and showed a moderate positive correlation 
between PRISMA Score and Year of Publication and also the number of trials included 
in meta-analyses. There was no evidence of association regarding the reporting quality 
of meta-analyses and the JIF or PRISMA endorsement of the Journal being published. 
Also, Cochrane Systematic reviews were not of higher reporting quality.  
Regarding the outcomes of the meta-analyses, most of them compared the efficacy of 
terlipressin vs placebo in reversal of HRS. Terlipressin was in all of them superior to 
placebo almost 4-times. On the other hand, Terlipressin was associated with more and 
more serious adverse events than placebo. Eight of the meta-analyses compared the 
efficacy of Terlipressin vs Noradrenaline in reversal of HRS. None of them proved 
superiority or inferiority of the one drug over the other. Also, they were associated with 
equal number of adverse events. Noradrenaline was related with more cardiovascular 
events in comparison with Terlipressin that was related mostly to abdominal events, as 
pain or diarrhea.  
Some limitations exist in the present study. The literature search was confined to 
electronic databases and there were language and time restriction. Compliance of the 
found meta-analyses with the inclusion criteria and their adherence to the PRISMA 
checklist was evaluated by only one author. The included studies were assessed only 
by PRISMA Statement, which is a tool of reporting only quality. In order for this review 
to be fully featured, the eligible studies should also have been assessed using 
methodological tools as AMSTAR Score.  
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Moreover, PRISMA Score was considered as value symbolizing quality in general of 
the meta-analysis. Regarding content, the meta-analyses included in this review were 
significantly heterogeneous. To begin with, five of the meta-analyses studied only 
patients with Type 1 Hepatorenal Syndrome and the in the remaining the percentage of 
HRS 1 and HRS 2 populations varied. Furthermore, the majority of meta-analyses were 
based on RCT’S with low to moderate quality and have high risk of bias. So a try to 
draw conclusions based on these studies will be risky.  
In conclusion, the last decade many meta-analyses, of moderate reporting quality 
according to PRISMA Statement, have been published studying the efficacy of 
Terlipressin in Hepatorenal syndrome. This review presented the strengths and 
weaknesses of these studies regarding their reporting quality and proved that the most 
recently published meta-analyses and those which include a larger amount of RCT’s 
are of higher quality. Some limitations exist mainly in literature search and in the great 
heterogeneity of the meta-analyses. Further studies of equivalence between Terlipressin 
and Noradrenaline should be performed. Finally, further reviews should include more 
meta-analyses and assess their quality with more than one tool in order general 
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